A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia

NACompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

September 9, 2021

Primary Completion Date

October 31, 2023

Study Completion Date

November 30, 2023

Conditions
Schizophrenia
Interventions
DRUG

Antipsychotic drugs

Stable antipsychotic medication 4 weeks before and during the treatment. Chlorpromazine (CPZ) equivalent dosages were calculated for second- and first-generation antipsychotic drugs

DEVICE

cTBS(the left temporoparietal cortex as the stimulation target)

Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks

DEVICE

cTBS (the left cerebellum Crus II as the stimulation target)

Participants received 3 daily sessions of cTBS treatment. One session of cTBS was 40 seconds in duration and consisted of 3-pulse bursts at 50 Hz repeated every 200 milliseconds (5 Hz) until a total of 600 pulses was reached. To achieve cumulative aftereffects, this protocol was repeated 3 times and (1800 pulses in total) separated by two 15 minute breaks

Trial Locations (1)

Unknown

The Second Xiangya Hospital of Central South University, Changsha

All Listed Sponsors
lead

Central South University

OTHER

NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia | Biotech Hunter | Biotech Hunter